Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.31 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036549 | 0.88 | NPFFR1 (0.34) | NPFFR1NPFFR2 | |
| SCHEMBL25753395 | 0.88 | NPFFR1 (0.34) | NPFFR1NPFFR2 | |
| SCHEMBL14333733 | 0.85 | KIF11 (0.41) | NPFFR1NPFFR2 | |
| SCHEMBL14333735 | 0.85 | KIF11 (0.41) | NPFFR1NPFFR2 | |
| SCHEMBL14333738 | 0.85 | KIF11 (0.41) | NPFFR1NPFFR2 | |
| SCHEMBL14333737 | 0.85 | KIF11 (0.41) | NPFFR1NPFFR2 | |
| SCHEMBL4933332 | 0.83 | ALDH1A1 (0.34) | — | |
| SCHEMBL4933334 | 0.83 | ALDH1A1 (0.34) | — | |
| SCHEMBL25753392 | 0.82 | NPFFR1 (0.34) | NPFFR1NPFFR2 | |
| SCHEMBL25622482 | 0.82 | NPFFR1 (0.34) | NPFFR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | PDE2A 2896/4885NPFFR1 1411/4885NPFFR2 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.